Muscarinic receptors full details for md exam answer to fetch 10/10 marks

Reading File

Finding Sources

Reading File

Loading Image

Finding Sources

Reading File

Finding Sources

I have all the data I need. Let me now compose the comprehensive, exam-grade answer.

Muscarinic Receptors - Complete MD Exam Answer

1. Introduction

Muscarinic receptors are G protein-coupled receptors (GPCRs) named after the alkaloid muscarine (from Amanita muscaria mushroom), which selectively activates them. They mediate the actions of acetylcholine (ACh) at parasympathetic neuroeffector junctions and in the CNS. They are pharmacologically distinct from nicotinic receptors (which are ligand-gated ion channels).

Natural ligand: Acetylcholine (rapidly hydrolyzed by AChE and BuChE)
Structure: 7-transmembrane (TM) domain GPCRs
Subtypes: Five cloned subtypes: M1 - M5

2. Structural Features

All five muscarinic receptor subtypes share:

Seven transmembrane (TM) helices (classic GPCR architecture)
A highly conserved orthosteric (classical) binding site buried deeply within the TM domain
Key interactions: charge-charge between the quaternary N of ACh and a TM3 aspartate residue; hydrogen bond with a TM6 asparagine (unique to muscarinic receptors among biogenic amine GPCRs)
Allosteric binding sites on extracellular loops (ECL2, ECL3) - these vary among subtypes, enabling subtype-selective modulators (PAMs/NAMs)

(Goodman & Gilman's, p. 227)

3. Subtypes, Location, G-Protein Coupling & Second Messengers

This is the single most important table for the exam:

Subtype	G-Protein	2nd Messenger	Key Locations	Selective Antagonist
M1	Gq/11	↑PLC → ↑IP3 → ↑[Ca²⁺]i; ↑DAG → ↑PKC	Cerebral cortex, hippocampus, striatum, autonomic ganglia, gastric parietal cells	Pirenzepine
M2	Gi/o	↓Adenylyl cyclase → ↓cAMP → ↓PKA; opens GIRK K⁺ channels	Heart (SA node, AV node), presynaptic nerve terminals (autoreceptor)	Gallamine, AF-DX 116
M3	Gq/11	↑PLC → ↑IP3 → ↑[Ca²⁺]i → ↑eNOS → ↑NO	Exocrine glands (salivary, lacrimal, bronchial, sweat), smooth muscle (bladder, bronchi, GI), vascular endothelium, eye (iris sphincter, ciliary)	Darifenacin, solifenacin, 4-DAMP
M4	Gi/o	↓Adenylyl cyclase → ↓cAMP	Striatum, CNS (modulates dopamine), presynaptic (brain)	Tropicamide (weak)
M5	Gq/11	↑PLC → ↑IP3	Substantia nigra, dopaminergic neurons, cerebral vessels	None clinically

Mnemonic: "Odd = Gq (1,3,5); Even = Gi (2,4)"

4. Signal Transduction - The Two Pathways

Muscarinic receptor G-protein signaling pathways showing M1/M3/M5 via Gq/PLC/IP3/Ca2+ and M2/M4 via Gi/AC inhibition/GIRK

Gq pathway (M1, M3, M5): Receptor → Gq/11 → Phospholipase C (PLC) → PIP2 hydrolysis → IP3 + DAG

IP3 → ER Ca²⁺ release → smooth muscle contraction, glandular secretion
DAG → Protein Kinase C activation
In vascular endothelium: Ca²⁺-calmodulin → eNOS activation → NO → cGMP → vasodilation

Gi/o pathway (M2, M4): Receptor → Gi/o → Inhibits adenylyl cyclase → ↓cAMP → ↓PKA

Gβγ subunit → opens GIRK (G protein-coupled inwardly-rectifying K⁺) channels → K⁺ efflux → hyperpolarization
Gβγ → inhibits voltage-dependent Ca²⁺ channels (VDCC)
Net cardiac effect: ↓heart rate, ↓conduction velocity

(Goodman & Gilman's, Fig. 11-1)

5. Organ-by-Organ Pharmacological Effects

Heart (M2 dominant)

SA node: ↓automaticity → negative chronotropic effect (bradycardia)
- Mechanism: ↓HCN channel activity (↓If pacemaker current); ↑IK-ACh (K⁺ efflux → hyperpolarization)
AV node: ↓conduction velocity → negative dromotropic effect (↑PR interval; can cause AV block)
Atria: ↓contractility (negative inotropic effect)
Ventricles: less affected (fewer M2 receptors)
Presynaptic M2: autoreceptors on vagal terminals, inhibit ACh release (feedback)

Blood Vessels (M3 on endothelium)

ACh → M3 on endothelial cells → ↑IP3 → ↑Ca²⁺ → eNOS → NO production → vasodilation
Note: If endothelium is damaged, ACh paradoxically causes vasoconstriction (direct M3 on vascular smooth muscle)

Respiratory (M3 on bronchial smooth muscle + glands)

Bronchoconstriction (↑IP3 → smooth muscle contraction)
↑Bronchial secretion
M1 on parasympathetic ganglia facilitates ganglionic transmission

Eye (M3)

Pupillary sphincter (iris): M3 → contraction → miosis
Ciliary muscle: M3 → contraction → accommodation for near vision (loss of far vision = loss of cycloplegia)

Gastrointestinal (M1, M3)

↑Peristalsis (↑GI motility); smooth muscle contraction
Internal sphincters relax
↑Gastric acid secretion (M1 on parietal cells and via gastrin release)
↑Salivary secretion (M3)

Urinary Tract (M3 dominant, M2 also present)

Detrusor muscle contraction → urination
Internal urethral sphincter relaxation
Both M2 and M3 mRNA predominate in human bladder; M3 drives contraction

Exocrine Glands (M3)

Salivary, lacrimal, bronchial, sweat glands: all increase secretion
Sweat glands are anatomically sympathetic but use ACh; blocked by atropine

CNS (M1 dominant; also M2, M4, M5)

High receptor density in hippocampus, cortex (M1), striatum (M1, M4)
M1: memory, cognition (target in Alzheimer's research)
M4: striatum - modulates dopamine (target in schizophrenia)
M5: on dopaminergic neurons in substantia nigra; cerebrovascular dilation

6. Distribution Summary

Tissue	Subtype	Effect
SA/AV node, atria	M2	Bradycardia, ↓conduction
Vascular endothelium	M3	NO-mediated vasodilation
Bronchial SM + glands	M3	Bronchoconstriction, ↑secretion
Bladder detrusor	M2+M3 (M3 functionally dominant)	Contraction (micturition)
GI smooth muscle	M3	Contraction, ↑motility
Salivary/lacrimal glands	M3	Secretion
Iris sphincter, ciliary	M3	Miosis, accommodation
Cerebral cortex, hippocampus	M1	Cognition, memory
Striatum	M1, M4	Motor control, DA modulation
Autonomic ganglia	M1	Ganglionic facilitation
Gastric parietal cells	M1	↑Acid secretion

7. Clinically Selective Muscarinic Antagonists

Drug	Selectivity	Clinical Use
Atropine	Non-selective	Bradycardia, organophosphate poisoning, preop
Scopolamine	Non-selective (CNS >> periphery)	Motion sickness, preoperative sedation
Pirenzepine	M1-selective	Peptic ulcer disease (↓gastric acid)
Ipratropium	Non-selective (quaternary - no CNS)	COPD, asthma (bronchodilation)
Tiotropium	M1/M3 > M2 (long-acting, kinetically selective)	COPD (once daily)
Oxybutynin, Tolterodine	M3 (bladder-selective)	Overactive bladder
Darifenacin, Solifenacin	M3-preferring	Overactive bladder (fewer cardiac SE)
Tropicamide	Non-selective (short duration)	Mydriasis/cycloplegia (eye exam)
Benzatropine, Trihexyphenidyl	Central	Parkinson's disease

Note: Quaternary ammonium muscarinic antagonists (ipratropium, glycopyrrolate, methscopolamine) do NOT cross the blood-brain barrier - used when central effects are unwanted.

8. Muscarinic Agonists (Exam Summary)

Drug	Properties	Use
Acetylcholine	Quaternary; rapid hydrolysis; poor oral bioavailability	Intraoperative miosis
Methacholine	β-methyl of ACh; resistant to AChE; predominantly muscarinic	Bronchoprovocation test
Carbachol	Resistant to all cholinesterases; nicotinic + muscarinic	Glaucoma (topical)
Bethanechol	Resistant to hydrolysis; selective muscarinic	Urinary retention, post-op/post-partum ileus
Pilocarpine	Tertiary amine (CNS penetration); partial agonist at some sites	Glaucoma, xerostomia
Muscarine	Quaternary; fungal toxin	Poisoning (Clitocybe, Inocybe mushrooms)

Tertiary amines (pilocarpine, arecoline) are orally absorbed and cross the BBB. Quaternary amines (carbachol, bethanechol, muscarine) are poorly absorbed and do not cross the BBB.

9. Muscarinic Toxidrome ("SLUDGE / DUMBELS")

SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI cramps, Emesis DUMBELS: Defecation/Diarrhea, Urination, Miosis, Bradycardia/Bronchospasm/Bronchorrhea, Emesis, Lacrimation, Salivation/Sweating

Caused by: organophosphates/carbamates (AChE inhibitors), Amanita/Clitocybe mushroom poisoning Treatment: Atropine (large doses for organophosphate poisoning) + pralidoxime (reactivates AChE before aging)

10. Allosteric Modulation (Advanced/Emerging)

Muscarinic receptors possess allosteric binding sites on extracellular loops distinct from the orthosteric site. These sites vary more among subtypes than the orthosteric site, enabling:

PAMs (positive allosteric modulators): enhance agonist efficacy (e.g., VU0357017 at M1)
NAMs (negative allosteric modulators): reduce agonist efficacy
Bitopic ligands: interact with both orthosteric + allosteric sites simultaneously for high subtype selectivity

This is a major area of drug development for Alzheimer's disease (M1 PAMs) and schizophrenia (M4 PAMs).

High-Yield Exam Points

M1, M3, M5 = Gq → PLC → IP3/DAG (odd numbers)
M2, M4 = Gi → ↓cAMP + GIRK channels (even numbers)
M2 = heart (bradycardia, ↓conduction)
M3 = smooth muscle + glands (the "effector" receptor)
M1 = CNS, ganglia, stomach
Atropine (non-selective antagonist) dose-response: secretions first → mydriasis → tachycardia → bladder → GI → last is gastric secretion
Muscarinic receptors on vascular endothelium are M3, but NO cholinergic nerve supply - ACh still causes vasodilation via endothelial NO
All clinical effects of ACh can be blocked by atropine (competitive antagonism)
Organophosphate poisoning = excess muscarinic (+ nicotinic) stimulation → treat with IV atropine
Tiotropium is "kinetically selective" for M3 > M2 because it dissociates slowly from M1/M3 but quickly from M2

Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed. (pp. 227-235); Katzung's Basic and Clinical Pharmacology, 16th Ed.; Campbell-Walsh Urology; Kaplan & Sadock's Psychiatry

This is a shared conversation. Sign in to Orris to start your own chat.